



Pfizer Inc
235 East 42nd St.
New York, NY 10017

April 2015

Dear Healthcare Provider,

In March 2015, Pfizer announced that it was able to start resupplying Norpace[®] CR (disopyramide phosphate extended-release capsules) 100 mg and 150 mg capsules following a shortage, but noted a chance of further drug shortage of either or both of the presentations through the third quarter of 2015.

With this letter we wish to update you on the supply availability of Norpace CR. More specifically, Pfizer is expecting to experience an interruption in supply of Norpace CR 100 mg capsules as early as middle to late April 2015; it is estimated that this product will be out of stock and on backorder in the United States until the third quarter of 2015. There continues to be a further chance of a drug shortage of the 150 mg presentation of Norpace[®] CR through the third quarter of 2015.

This shortage is not related to any safety or efficacy concerns, but due to a manufacturing event. The reason for the interruption in supply does not impact the quality, safety or efficacy of the finished product currently available on the market.

Pfizer recognizes the importance of Norpace[®] CR to you and your patients and remains committed to this product. There is no impact to Norpace[®] (disopyramide phosphate) capsules. Healthcare providers should use their clinical judgment and expertise to determine treatment options for their patients.

We regret any inconvenience this shortage may have caused. For medical questions on Norpace[®] CR, please contact 1-800-438-1985. The full Prescribing Information for Norpace[®] and Norpace[®] CR can be found at: http://www.pfizer.com/files/products/uspi_norpace.pdf.

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

Sincerely,

Pol Vandenbroucke, MD

A handwritten signature in black ink that reads "Pol Vandenbroucke".

Regional Head Medical Affairs, North America
Global Established Pharma, Pfizer Inc

[Please see accompanying Full Prescribing Information, including BOXED WARNING for Norpace and Norpace[®] CR.](#)

(c) 2015 Pfizer Inc. All rights reserved. NST739707-01